Bathija R, Gupta N, Zangwill L, Weinreb RN. Changing definition of glaucoma. J Glaucoma. 1998 Jun. 7(3):165-9. [QxMD MEDLINE Link].
Van Buskirk EM, Cioffi GA. Glaucomatous optic neuropathy. Am J Ophthalmol. 1992 Apr 15. 113(4):447-52. [QxMD MEDLINE Link].
Costa VP, Jimenez-Roman J, Carrasco FG, Lupinacci A, Harris A. Twenty-four-hour ocular perfusion pressure in primary open-angle glaucoma. Br J Ophthalmol. 2010 Oct. 94(10):1291-4. [QxMD MEDLINE Link].
Czudowska MA, Ramdas WD, Wolfs RC, Hofman A, De Jong PT, Vingerling JR, et al. Incidence of Glaucomatous Visual Field Loss: A Ten-Year Follow-up from the Rotterdam Study. Ophthalmology. 2010 Sep. 117(9):1705-12. [QxMD MEDLINE Link].
Lee CS, Larson EB, Gibbons LE, Lee AY, McCurry SM, Bowen JD, et al. Associations between recent and established ophthalmic conditions and risk of Alzheimer's disease. Alzheimers Dement. 2018 Aug 2. [QxMD MEDLINE Link].
McNamara D. Predictors of Rapid Glaucoma Progression Identified. Medscape Medical News. Available at http://www.medscape.com/viewarticle/805049. Accessed: June 13,2023.
De Moraes CG, Juthani VJ, Liebmann JM, Teng CC, Tello C, Susanna R Jr, et al. Risk factors for visual field progression in treated glaucoma. Arch Ophthalmol. 2011 May. 129(5):562-8. [QxMD MEDLINE Link].
Rao HL, Kumar AU, Babu JG, Senthil S, Garudadri CS. Relationship between Severity of Visual Field Loss at Presentation and Rate of Visual Field Progression in Glaucoma. Ophthalmology. 2011 Feb. 118(2):249-53. [QxMD MEDLINE Link].
Nouri-Mahdavi K, Zarei R, Caprioli J. Influence of visual field testing frequency on detection of glaucoma progression with trend analyses. Arch Ophthalmol. 2011 Dec. 129(12):1521-7. [QxMD MEDLINE Link].
Traynis I, De Moraes CG, Raza AS, Liebmann JM, Ritch R, Hood DC. Prevalence and nature of early glaucomatous defects in the central 10° of the visual field. JAMA Ophthalmol. 2014 Jan 9. [QxMD MEDLINE Link].
Laidman J. Early glaucoma damage sometimes missed by visual field test. Medscape Medical News. January 17, 2014. [Full Text].
Leung CK, Yu M, Weinreb RN, Lai G, Xu G, Lam DS. Retinal Nerve Fiber Layer Imaging with Spectral-domain Optical Coherence Tomography: Patterns of Retinal Nerve Fiber Layer Progression. Ophthalmology. 2012 Jun 5. [QxMD MEDLINE Link].
Leung CK, Liu S, Weinreb RN, et al. Evaluation of retinal nerve fiber layer progression in glaucoma a prospective analysis with neuroretinal rim and visual field progression. Ophthalmology. 2011 Aug. 118(8):1551-7. [QxMD MEDLINE Link].
Medeiros FA, Zangwill LM, Anderson DR, Liebmann JM, Girkin CA, Harwerth RS, et al. Estimating the Rate of Retinal Ganglion Cell Loss in Glaucoma. Am J Ophthalmol. 2012 Jul 26. [QxMD MEDLINE Link].
Chihara E. Assessment of true intraocular pressure: the gap between theory and practical data. Surv Ophthalmol. 2008 May-Jun. 53(3):203-18. [QxMD MEDLINE Link].
ElMallah MK, Asrani SG. New ways to measure intraocular pressure. Curr Opin Ophthalmol. 2008 Mar. 19(2):122-6. [QxMD MEDLINE Link].
Annette H, Kristina L, Bernd S, Mark-Oliver F, Wolfgang W. Effect of central corneal thickness and corneal hysteresis on tonometry as measured by dynamic contour tonometry, ocular response analyzer, and Goldmann tonometry in glaucomatous eyes. J Glaucoma. 2008 Aug. 17(5):361-5. [QxMD MEDLINE Link].
Kaufmann C, Bachmann LM, Thiel MA. Comparison of dynamic contour tonometry with goldmann applanation tonometry. Invest Ophthalmol Vis Sci. 2004 Sep. 45(9):3118-21. [QxMD MEDLINE Link].
Reichert, Inc. The Ocular Response Analyzer. Available at http://www.ocularresponseanalyzer.com/. Accessed: June 13, 2023.
Heijl A, Peters D, Leske MC, Bengtsson B. Effects of argon laser trabeculoplasty in the early manifest glaucoma trial. Am J Ophthalmol. 2011 Nov. 152(5):842-8. [QxMD MEDLINE Link].
Francis BA, Hong B, Winarko J, et al. Vision loss and recovery after trabeculectomy: risk and associated risk factors. Arch Ophthalmol. 2011 Aug. 129(8):1011-7. [QxMD MEDLINE Link].
Allen RC, Netland PA, eds. Glaucoma Medical Therapy: Principles and Management. American Academy of Ophthalmology; 1999.
Rocklatan (netarsudil and latanoprost ophthalmic solution) [package insert]. Irvine, CA: Aerie Pharmaceuticals. March, 2019. Available at [Full Text].
Serle JB, Katz LJ, McLaurin E, Heah T, Ramirez-Davis N, Usner DW, et al. Two Phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure. Am J Ophthalmol. 2017 Nov 30. [QxMD MEDLINE Link].
Alward WL. The genetics of open-angle glaucoma: the story of GLC1A and myocilin. Eye. 2000 Jun. 14 (Pt 3B):429-36. [QxMD MEDLINE Link].
American Academy of Ophthalmology. Preferred Practice Patterns: Primary Open Angle Glaucoma Suspect and POAG. 1995-1996.
Ang GS, Bochmann F, Townend J, et al. Corneal biomechanical properties in primary open angle glaucoma and normal tension glaucoma. J Glaucoma. 2008 Jun-Jul. 17(4):259-62. [QxMD MEDLINE Link].
Ashaye AO, Adeoye AO. Characteristics of patients who dropout from a glaucoma clinic. J Glaucoma. 2008 Apr-May. 17(3):227-32. [QxMD MEDLINE Link].
Aung T, Chew PT, Yip CC, et al. A randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 2001 May. 131(5):636-42. [QxMD MEDLINE Link].
Azuara-Blanco A, Burr JM. Assessment of glaucoma imaging technology. Ophthalmology. 2008 Jul. 115(7):1266-7; author reply 1267-8. [QxMD MEDLINE Link].
Bakri SJ, McCannel CA, Edwards AO, et al. Persisent ocular hypertension following intravitreal ranibizumab. Graefes Arch Clin Exp Ophthalmol. 2008 Jul. 246(7):955-8. [QxMD MEDLINE Link].
Beckers HJ, Schouten JS, Webers CA, et al. Side effects of commonly used glaucoma medications: comparison of tolerability, chance of discontinuation, and patient satisfaction. Graefes Arch Clin Exp Ophthalmol. 2008 Oct. 246(10):1485-90. [QxMD MEDLINE Link].
Bengtsson B. A new rapid threshold algorithm for short-wavelength automated perimetry. Invest Ophthalmol Vis Sci. 2003 Mar. 44(3):1388-94. [QxMD MEDLINE Link].
Bengtsson B, Heijl A. Normal intersubject threshold variability and normal limits of the SITA SWAP and full threshold SWAP perimetric programs. Invest Ophthalmol Vis Sci. 2003 Nov. 44(11):5029-34. [QxMD MEDLINE Link].
Berdahl JP, Allingham RR, Johnson DH. Cerebrospinal fluid pressure is decreased in primary open-angle glaucoma. Ophthalmology. 2008 May. 115(5):763-8. [QxMD MEDLINE Link].
Berisha F, Feke GT, Hirose T, et al. Retinal blood flow and nerve fiber layer measurements in early-stage open-angle glaucoma. Am J Ophthalmol. 2008 Sep. 146(3):466-472. [QxMD MEDLINE Link].
Bramley T, Peeples P, Walt JG, et al. Impact of vision loss on costs and outcomes in medicare beneficiaries with glaucoma. Arch Ophthalmol. 2008 Jun. 126(6):849-56. [QxMD MEDLINE Link].
Brandt JD. Corneal thickness in glaucoma screening, diagnosis, and management. Curr Opin Ophthalmol. 2004 Apr. 15(2):85-9. [QxMD MEDLINE Link].
Brandt JD, Beiser JA, Gordon MO, et al. Central corneal thickness and measured IOP response to topical ocular hypotensive medication in the Ocular Hypertension Treatment Study. Am J Ophthalmol. 2004 Nov. 138(5):717-22. [QxMD MEDLINE Link].
Brandt JD, Beiser JA, Kass MA, et al. Central corneal thickness in the Ocular Hypertension Treatment Study (OHTS). Ophthalmology. 2001 Oct. 108(10):1779-88. [QxMD MEDLINE Link].
Brown T. FDA Approves Simbrinza for Glaucoma, Ocular Hypertension. Medscape Medical News. Available at http://www.medscape.com/viewarticle/803064. Accessed: June 23, 2023.
Brubaker RF. Mechanism of action of bimatoprost (Lumigan). Surv Ophthalmol. 2001 May. 45 Suppl 4:S347-51. [QxMD MEDLINE Link].
Bruhn RL, Stamer WD, Herrygers LA, et al. Relationship between Glaucoma and Selenium Levels in Plasma and Aqueous Humor. Br J Ophthalmol. 2008 Jun 12. [QxMD MEDLINE Link].
Brusini P, Salvetat ML, Zeppieri M, et al. Comparison of ICare tonometer with Goldmann applanation tonometer in glaucoma patients. J Glaucoma. 2006 Jun. 15(3):213-7. [QxMD MEDLINE Link].
Cantor L. Section 10: Glaucoma. Basic and Clinical Science Course. American Academy of Ophthalmology; 1996-1997.
Chaudhry I, Wong S. Recognizing glaucoma. A guide for the primary care physician. Postgrad Med. 1996 May. 99(5):247-8, 251-2, 257-9, Pass;M. [QxMD MEDLINE Link].
Chauhan BC. Endothelin and its potential role in glaucoma. Can J Ophthalmol. 2008 Jun. 43(3):356-60. [QxMD MEDLINE Link].
Chen TC, Ahn Yuen SJ, Sangalang MA, Fernando RE, Leuenberger EU. Retrobulbar chlorpromazine injections for the management of blind and seeing painful eyes. J Glaucoma. 2002 Jun. 11(3):209-13. [QxMD MEDLINE Link].
Cheung W, Guo L, Cordeiro MF. Neuroprotection in glaucoma: drug-based approaches. Optom Vis Sci. 2008 Jun. 85(6):406-16. [QxMD MEDLINE Link].
Chihara E. Assessment of true intraocular pressure: the gap between theory and practical data. Surv Ophthalmol. 2008 May-Jun. 53(3):203-18. [QxMD MEDLINE Link].
Cioffi GA, Latina MA, Schwartz GF. Argon versus selective laser trabeculoplasty. J Glaucoma. 2004 Apr. 13(2):174-7. [QxMD MEDLINE Link].
Colton T, Ederer F. The distribution of intraocular pressures in the general population. Surv Ophthalmol. 1980 Nov-Dec. 25(3):123-9. [QxMD MEDLINE Link].
Cox JA, Mollan SP, Bankart J, et al. Efficacy of antiglaucoma fixed combination therapy versus unfixed components in reducing intraocular pressure: a systematic review. Br J Ophthalmol. 2008 Jun. 92(6):729-34. [QxMD MEDLINE Link].
Craven ER, Walters TR, Williams R, et al. Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 2005 Aug. 21(4):337-48. [QxMD MEDLINE Link].
Deokule S, Weinreb RN. Relationships among systemic blood pressure, intraocular pressure, and open-angle glaucoma. Can J Ophthalmol. 2008 Jun. 43(3):302-7. [QxMD MEDLINE Link].
Dhaliwal JS, Mason BF, Kaufman SC. Long-term use of topical tacrolimus (FK506) in high-risk penetrating keratoplasty. Cornea. 2008 May. 27(4):488-93. [QxMD MEDLINE Link].
Doughty MJ, Zaman ML. Human corneal thickness and its impact on intraocular pressure measures: a review and meta-analysis approach. Surv Ophthalmol. 2000 Mar-Apr. 44(5):367-408. [QxMD MEDLINE Link].
ElMallah MK, Asrani SG. New ways to measure intraocular pressure. Curr Opin Ophthalmol. 2008 Mar. 19(2):122-6. [QxMD MEDLINE Link].
Eskridge JB. Ocular hypertension or early undetected glaucoma?. J Am Optom Assoc. 1987 Sep. 58(9):747-69. [QxMD MEDLINE Link].
Filippopoulos T, Rhee DJ. Novel surgical procedures in glaucoma: advances in penetrating glaucoma surgery. Curr Opin Ophthalmol. 2008 Mar. 19(2):149-54. [QxMD MEDLINE Link].
Gedde SJ, Schiffman JC, Feuer WJ, Herndon LW, Brandt JD, Budenz DL. Treatment outcomes in the tube versus trabeculectomy study after one year of follow-up. Am J Ophthalmol. 2007 Jan. 143(1):9-22. [QxMD MEDLINE Link].
George MK, Emerson JW, Cheema SA, et al. Evaluation of a modified protocol for selective laser trabeculoplasty. J Glaucoma. 2008 Apr-May. 17(3):197-202. [QxMD MEDLINE Link].
Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002 Jun. 120(6):714-20; discussion 829-30. [QxMD MEDLINE Link].
Gordon MO, Kass MA. The Ocular Hypertension Treatment Study: design and baseline description of the participants. Arch Ophthalmol. 1999 May. 117(5):573-83. [QxMD MEDLINE Link].
Greenfield DS, Girkin C, Kwon YH. Memantine and progressive glaucoma. J Glaucoma. 2005 Feb. 14(1):84-6. [QxMD MEDLINE Link].
Greenfield DS, Weinreb RN. Role of optic nerve imaging in glaucoma clinical practice and clinical trials. Am J Ophthalmol. 2008 Apr. 145(4):598-603. [QxMD MEDLINE Link].
Grus F, Sun D. Immunological mechanisms in glaucoma. Semin Immunopathol. 2008 Apr. 30(2):121-6. [QxMD MEDLINE Link].
Grus FH, Joachim SC, Wuenschig D, et al. Autoimmunity and glaucoma. J Glaucoma. 2008 Jan-Feb. 17(1):79-84. [QxMD MEDLINE Link].
Gupta N, Weinreb RN. New definitions of glaucoma. Curr Opin Ophthalmol. 1997 Apr. 8(2):38-41. [QxMD MEDLINE Link].
Halkiadakis I, Kipioti A, Emfietzoglou I, et al. Comparison of optical coherence tomography and scanning laser polarimetry in glaucoma, ocular hypertension, and suspected glaucoma. Ophthalmic Surg Lasers Imaging. 2008 Mar-Apr. 39(2):125-32. [QxMD MEDLINE Link].
Hernandez R, Rabindranath K, Fraser C, et al. Screening for open angle glaucoma: systematic review of cost-effectiveness studies. J Glaucoma. 2008 Apr-May. 17(3):159-68. [QxMD MEDLINE Link].
Hitchings RA. Glaucoma: current thinking. Br J Hosp Med. 1996 Mar 20-Apr 2. 55(6):312-4. [QxMD MEDLINE Link].
Hodapp EA, Anderson DR. Treatment of early glaucoma. In: Focal Points. Vol 4. 1986.
Holz HA, Lim MC. Glaucoma lasers: a review of the newer techniques. Curr Opin Ophthalmol. 2005 Apr. 16(2):89-93. [QxMD MEDLINE Link].
Hoskins HD Jr. The management of elevated intraocular pressure with normal optic discs and visual fields. II. An approach to early therapy. Surv Ophthalmol. 1977 May-Jun. 21(6):479, 489-93. [QxMD MEDLINE Link].
Inatani M, Iwao K, Inoue T, et al. Long-term relationship between intraocular pressure and visual field loss in primary open-angle glaucoma. J Glaucoma. 2008 Jun-Jul. 17(4):275-9. [QxMD MEDLINE Link].
Jacobi S, Dubielzig RR. Feline primary open angle glaucoma. Vet Ophthalmol. 2008 May-Jun. 11(3):162-5. [QxMD MEDLINE Link].
Jamil AL, Mills RP. Glaucoma tube or trabeculectomy? That is the question. Am J Ophthalmol. 2007 Jan. 143(1):141-2. [QxMD MEDLINE Link].
Johnson TD, Zimmerman TJ. Ocular hypertension, glaucoma suspect, preglaucoma, or glaucoma? Synopsis of views. Ann Ophthalmol. 1986 Nov. 18(11):313-4. [QxMD MEDLINE Link].
Juzych MS, Chopra V, Banitt MR, et al. Comparison of long-term outcomes of selective laser trabeculoplasty versus argon laser trabeculoplasty in open-angle glaucoma. Ophthalmology. 2004 Oct. 111(10):1853-9. [QxMD MEDLINE Link].
Kahook MY, Noecker RJ. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears. Cornea. 2008 Apr. 27(3):339-43. [QxMD MEDLINE Link].
Kass MA. When to treat ocular hypertension (with discussion). Surv Ophthalmol. 1980. 28(Supp.):229-234.
Kass MA, Hart WM Jr, Gordon M, et al. Risk factors favoring the development of glaucomatous visual field loss in ocular hypertension. Surv Ophthalmol. 1980 Nov-Dec. 25(3):155-62. [QxMD MEDLINE Link].
Kawasaki R, Wang JJ, Rochtchina E, Lee AJ, Wong TY, Mitchell P. Retinal vessel caliber is associated with the 10-year incidence of glaucoma: the Blue Mountains Eye Study. Ophthalmology. 2013 Jan. 120(1):84-90. [QxMD MEDLINE Link].
Kiekens S, Veva De Groot, Coeckelbergh T, et al. Continuous positive airway pressure therapy is associated with an increase in intraocular pressure in obstructive sleep apnea. Invest Ophthalmol Vis Sci. 2008 Mar. 49(3):934-40. [QxMD MEDLINE Link].
Krupin T, Liebmann JM, Greenfield DS, et al. The Low-pressure Glaucoma Treatment Study (LoGTS) study design and baseline characteristics of enrolled patients. Ophthalmology. 2005 Mar. 112(3):376-85. [QxMD MEDLINE Link].
Ku JY, Danesh-Meyer HV, Craig JP, et al. Comparison of intraocular pressure measured by Pascal dynamic contour tonometry and Goldmann applanation tonometry. Eye. 2006 Feb. 20(2):191-8. [QxMD MEDLINE Link].
Lacey J, Cate H, Broadway DC. Barriers to adherence with glaucoma medications: a qualitative research study. Eye. 2008 Apr 25. [QxMD MEDLINE Link].
Landers JA, Goldberg I, Graham SL. Detection of early visual field loss in glaucoma using frequency-doubling perimetry and short-wavelength automated perimetry. Arch Ophthalmol. 2003 Dec. 121(12):1705-10. [QxMD MEDLINE Link].
Lasseck J, Jehle T, Feltgen N, et al. Comparison of intraocular tonometry using three different non-invasive tonometers in children. Graefes Arch Clin Exp Ophthalmol. 2008 Oct. 246(10):1463-6. [QxMD MEDLINE Link].
Latina MA, Gulati V. Selective laser trabeculoplasty: stimulating the meshwork to mend its ways. Int Ophthalmol Clin. 2004. 44(1):93-103. [QxMD MEDLINE Link].
Latina MA, Tumbocon JA. Selective laser trabeculoplasty: a new treatment option for open angle glaucoma. Curr Opin Ophthalmol. 2002 Apr. 13(2):94-6. [QxMD MEDLINE Link].
Lebrun-Julien F, Di Polo A. Molecular and cell-based approaches for neuroprotection in glaucoma. Optom Vis Sci. 2008 Jun. 85(6):417-24. [QxMD MEDLINE Link].
Lee PP, Walt JW, Rosenblatt LC, et al. Association between intraocular pressure variation and glaucoma progression: data from a United States chart review. Am J Ophthalmol. 2007 Dec. 144(6):901-907. [QxMD MEDLINE Link].
Leske MC, Connell AM, Wu SY, et al. Distribution of intraocular pressure. The Barbados Eye Study. Arch Ophthalmol. 1997 Aug. 115(8):1051-7. [QxMD MEDLINE Link].
Levin LA, Peeples P. History of neuroprotection and rationale as a therapy for glaucoma. Am J Manag Care. 2008 Feb. 14(1 Suppl):S11-4. [QxMD MEDLINE Link].
Li HK, Tang RA, Oschner K, et al. Telemedicine screening of glaucoma. Telemed J. 1999 Fall. 5(3):283-90. [QxMD MEDLINE Link].
Liesegang TJ. Glaucoma: changing concepts and future directions. Mayo Clin Proc. 1996 Jul. 71(7):689-94. [QxMD MEDLINE Link].
Lin SC. Endoscopic and transscleral cyclophotocoagulation for the treatment of refractory glaucoma. J Glaucoma. 2008 Apr-May. 17(3):238-47. [QxMD MEDLINE Link].
Lin SC. Endoscopic and transscleral cyclophotocoagulation for the treatment of refractory glaucoma. J Glaucoma. 2008 Apr-May. 17(3):238-47. [QxMD MEDLINE Link].
Lin SC, Singh K, Jampel HD, Hodapp EA, Smith SD, Francis BA, et al. Optic nerve head and retinal nerve fiber layer analysis: a report by the American Academy of Ophthalmology. Ophthalmology. 2007 Oct. 114(10):1937-49. [QxMD MEDLINE Link].
Linner E. The natural course of ocular pressure in ocular hypertension. Surv Ophthalmol. 1980 Nov-Dec. 25(3):136-8. [QxMD MEDLINE Link].
Lipton SA. Possible role for memantine in protecting retinal ganglion cells from glaucomatous damage. Surv Ophthalmol. 2003 Apr. 48 Suppl 1:S38-46. [QxMD MEDLINE Link].
Liu J, Roberts CJ. Influence of corneal biomechanical properties on intraocular pressure measurement: quantitative analysis. J Cataract Refract Surg. 2005 Jan. 31(1):146-55. [QxMD MEDLINE Link].
Madadi P, Koren G, Freeman DJ, et al. Timolol concentrations in breast milk of a woman treated for glaucoma: calculation of neonatal exposure. J Glaucoma. 2008 Jun-Jul. 17(4):329-31. [QxMD MEDLINE Link].
Medeiros FA, Zangwill LM, Bowd C, et al. Comparison of the GDx VCC scanning laser polarimeter, HRT II confocal scanning laser ophthalmoscope, and stratus OCT optical coherence tomograph for the detection of glaucoma. Arch Ophthalmol. 2004 Jun. 122(6):827-37. [QxMD MEDLINE Link].
Memarzadeh F, Ying-Lai M, Azen SP, et al. Associations with intraocular pressure in Latinos: the Los Angeles Latino Eye Study. Am J Ophthalmol. 2008 Jul. 146(1):69-76. [QxMD MEDLINE Link].
Migdal C. Glaucoma medical treatment: philosophy, principles and practice. Eye. 2000 Jun. 14 (Pt 3B):515-8. [QxMD MEDLINE Link].
Miglior S, Casula M, Guareschi M, et al. Clinical ability of Heidelberg retinal tomograph examination to detect glaucomatous visual field changes. Ophthalmology. 2001 Sep. 108(9):1621-7. [QxMD MEDLINE Link].
Milla E, Duch S, Buchacra O, et al. Poor agreement between Goldmann and Pascal tonometry in eyes with extreme pachymetry. Eye. 2008 Mar 28. [QxMD MEDLINE Link].
Minckler DS. Histology of optic nerve damage in ocular hypertension and early glaucoma. Surv Ophthalmol. 1989 Apr. 33 Suppl:401-2; discussion 409-11. [QxMD MEDLINE Link].
Naskar R, Dreyer EB. New horizons in neuroprotection. Surv Ophthalmol. 2001 May. 45 Suppl 3:S250-5; discussion S273-6. [QxMD MEDLINE Link].
Nouri-Mahdavi K, Nikkhou K, Hoffman DC, et al. Detection of early glaucoma with optical coherence tomography (StratusOCT). J Glaucoma. 2008 Apr-May. 17(3):183-8. [QxMD MEDLINE Link].
Phelps CD. The no treatment approach to ocular hypertension. Surv Ophthalmol. 1980 Nov-Dec. 25(3):175-82. [QxMD MEDLINE Link].
Poli A, Strouthidis NG, Ho TA, et al. Analysis of HRT images: comparison of reference planes. Invest Ophthalmol Vis Sci. 2008 Sep. 49(9):3970-5. [QxMD MEDLINE Link].
Quigley HA, Enger C, Katz J, et al. Risk factors for the development of glaucomatous visual field loss in ocular hypertension. Arch Ophthalmol. 1994 May. 112(5):644-9. [QxMD MEDLINE Link].
Qureshi IA. Effects of mild, moderate and severe exercise on intraocular pressure of sedentary subjects. Ann Hum Biol. 1995 Nov-Dec. 22(6):545-53. [QxMD MEDLINE Link].
Racette L, Sample PA. Short-wavelength automated perimetry. Ophthalmol Clin North Am. 2003 Jun. 16(2):227-36, vi-vii. [QxMD MEDLINE Link].
Reeder CE, Franklin M, Bramley TJ. Managed care and the impact of glaucoma. Am J Manag Care. 2008 Feb. 14(1 Suppl):S5-S10. [QxMD MEDLINE Link].
Reus NJ, Colen TP, Lemij HG. The prevalence of glaucomatous defects with short-wavelength automated perimetry in patients with elevated intraocular pressures. J Glaucoma. 2005 Feb. 14(1):26-9. [QxMD MEDLINE Link].
Ritch, Shields, Krupin, eds. The Glaucomas. 2nd ed. 1992.
Rivera JL, Bell NP, Feldman RM. Risk factors for primary open angle glaucoma progression: what we know and what we need to know. Curr Opin Ophthalmol. 2008 Mar. 19(2):102-6. [QxMD MEDLINE Link].
Roach L. Narrow retinal vessels raise risk for open-angle glaucoma. Medscape Medical News. January 9, 2013. Available at http://www.medscape.com/viewarticle/777428. Accessed: June 13,2023.
Roizen A, Ela-Dalman N, Velez FG, et al. Surgical treatment of strabismus secondary to glaucoma drainage device. Arch Ophthalmol. 2008 Apr. 126(4):480-6. [QxMD MEDLINE Link].
Sahin A, Niyaz L, Yildirim N. Comparison of the rebound tonometer with the Goldmann applanation tonometer in glaucoma patients. Clin Experiment Ophthalmol. 2007 May-Jun. 35(4):335-9. [QxMD MEDLINE Link].
Schuman JS. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension. Surv Ophthalmol. 1996 Nov. 41 Suppl 1:S27-37. [QxMD MEDLINE Link].
Serle JB. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III. Surv Ophthalmol. 1996 Nov. 41 Suppl 1:S39-47. [QxMD MEDLINE Link].
Shields MB. Textbook of Glaucoma. 4th ed. Lippincott Williams & Wilkins; 1998.
Shih CY, Graff Zivin JS, Trokel SL, et al. Clinical significance of central corneal thickness in the management of glaucoma. Arch Ophthalmol. 2004 Sep. 122(9):1270-5. [QxMD MEDLINE Link].
Siam GA, Gheith ME, de Barros DS, et al. Limitations of the Heidelberg Retina Tomograph. Ophthalmic Surg Lasers Imaging. 2008 May-Jun. 39(3):262-4. [QxMD MEDLINE Link].
Spaeth GL. Early primary open-angle glaucoma: diagnosis and management. Preface. Int Ophthalmol Clin. 1979 Spring. 19(1):vii-ix. [QxMD MEDLINE Link].
Stamper RL, Lieberman MF, Drake MV. Becker-Shaffers Diagnosis and Therapy of the Glaucomas. 7th ed. Mosby-Year Book; 1999.
Sunaric-Megevand G, Leuenberger PM. Results of viscocanalostomy for primary open-angle glaucoma. Am J Ophthalmol. 2001 Aug. 132(2):221-8. [QxMD MEDLINE Link].
Svizenska I, Dubovy P, Sulcova A. Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures - A short review. Pharmacol Biochem Behav. 2008 May 25. [QxMD MEDLINE Link].
Tezel G, Kolker AE, Kass MA, et al. Parapapillary chorioretinal atrophy in patients with ocular hypertension. I. An evaluation as a predictive factor for the development of glaucomatous damage. Arch Ophthalmol. 1997 Dec. 115(12):1503-8. [QxMD MEDLINE Link].
Tezel G, Kolker AE, Wax MB, et al. Parapapillary chorioretinal atrophy in patients with ocular hypertension. II. An evaluation of progressive changes. Arch Ophthalmol. 1997 Dec. 115(12):1509-14. [QxMD MEDLINE Link].
Van Buskirk EM. Medicolegal aspects of glaucoma care. Surv Ophthalmol. 1998 Jul-Aug. 43(1):83-6. [QxMD MEDLINE Link].
Woodward DF, Krauss AH, Chen J, et al. The pharmacology of bimatoprost (Lumigan). Surv Ophthalmol. 2001 May. 45 Suppl 4:S337-45. [QxMD MEDLINE Link].
Yu DY, Su EN, Cringle SJ, et al. Comparison of the vasoactive effects of the docosanoid unoprostone and selected prostanoids on isolated perfused retinal arterioles. Invest Ophthalmol Vis Sci. 2001 Jun. 42(7):1499-504. [QxMD MEDLINE Link].
Yu JY, Kahook MY, Lathrop KL, et al. The effect of probe placement and type of viscoelastic material on endoscopic cyclophotocoagulation laser energy transmission. Ophthalmic Surg Lasers Imaging. 2008 Mar-Apr. 39(2):133-6. [QxMD MEDLINE Link].
Yucel YH, Gupta N. Paying attention to the cerebrovascular system in glaucoma. Can J Ophthalmol. 2008 Jun. 43(3):342-6. [QxMD MEDLINE Link].
Zangwill LM, Jain S, Racette L, et al. The effect of disc size and severity of disease on the diagnostic accuracy of the Heidelberg Retina Tomograph Glaucoma Probability Score. Invest Ophthalmol Vis Sci. 2007 Jun. 48(6):2653-60. [QxMD MEDLINE Link].

Media Gallery

Advanced glaucomatous damage with increased cupping and substantial pallor of the optic nerve head. Courtesy of M. Bruce Shields, MD.
Flowchart for evaluation of a patient with suspected glaucoma. Used by permission of the American Academy of Ophthalmology.
Diagram of intraocular pressure distribution, with a visible skew to the right (somewhat exaggerated compared to the actual distribution). Note that, while uncommon, field loss among individuals with pressures in the upper teens can occur. Also, note that the average pressure among those with glaucomas is in the low 20s, even though most individuals with pressures in the low 20s do not have glaucoma. Used by permission from Survey of Ophthalmology.
Diagram showing the relative proportion of people in the general population who have elevated pressure (horizontally shaded lines) and/or damage from glaucoma (vertically shaded lines). Notice that most have elevated pressure but no sign of damage (ie, ocular hypertensives), but there are also those with normal pressures who still have damage from glaucoma (ie, normal tension glaucoma). Courtesy of M. Bruce Shields, MD.OHT = horizontal lines only NTG = vertical lines only POAG and other glaucomas with both elevated intraocular pressure and damage = overlapping horizontal and vertical lines
Humphrey visual field, right eye, showing patient with advanced glaucomatous field loss. Notice both the arcuate extension from the blind spot (Bjerrum scotoma) and the loss nasally (nasal step), which often occurs early in the disease process. Courtesy of M. Bruce Shields, MD.
Illustration of progressive optic nerve damage. Notice the deepening (saucerization) along the neural rim, along with notching and increased excavation/sloping of the optic nerve and circumlinear vessel inferiorly. Courtesy of M. Bruce Shields, MD.
Example of progressive visual field loss over time (from top to bottom) in a patient with glaucoma. Notice the early appearance of an inferior nasal step and arcuate loss, with progressive enlargement and increasing density of the scotomata over time. Courtesy of M. Bruce Shields, MD.
Optic nerve asymmetry in a patient with glaucomatous damage, left eye, showing optic nerve excavation inferiorly (similar to Image 5). Courtesy of M. Bruce Shields, MD.
Glaucomatous optic nerve damage, with sloping and nerve fiber layer rim hemorrhage at the 7-o'clock position. Hemorrhage is indicative of progressive damage, usually due to inadequate pressure control. Further notching and pallor corresponding to the area of hemorrhage usually is seen several weeks after resorption of the blood. Courtesy of M. Bruce Shields, MD.
Correction values according to corneal thickness.
Ocular hypertension study (OHTS). Percentage of patients who developed glaucoma during this study, stratified by baseline intraocular pressure (IOP) and central corneal thickness (CCT).
Intraocular pressure measurements. Adapted from Reichert Ophthalmic Instruments, Ocular Response Analyzer, How does it work Web page.

of 12

Author

Kristin S Biggerstaff, MD, MS Glaucoma Specialist, Kansas City Eye Clinic

Kristin S Biggerstaff, MD, MS is a member of the following medical societies: American Academy of Ophthalmology, American Glaucoma Society

Disclosure: Nothing to disclose.

Coauthor(s)

Albert P Lin, MD Assistant Professor, Department of Ophthalmology, Baylor College of Medicine; Staff Physician, Michael E DeBakey Veterans Affairs Medical Center; Ophthalmologist, Ophthalmology Consultants of Houston

Albert P Lin, MD is a member of the following medical societies: American Academy of Ophthalmology, American Glaucoma Society, Harris County Medical Society, Texas Medical Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Martin B Wax, MD Professor, Department of Ophthalmology, University of Texas Southwestern Medical School; Vice President, Research and Development, Head, Ophthalmology Discovery Research and Preclinical Sciences, Alcon Laboratories, Inc

Martin B Wax, MD is a member of the following medical societies: American Academy of Ophthalmology, American Glaucoma Society, Society for Neuroscience

Disclosure: Nothing to disclose.

Chief Editor

Inci Irak Dersu, MD, MPH Clinical Professor of Ophthalmology, State University of New York Downstate College of Medicine; Attending Physician, SUNY Downstate Medical Center, Kings County Hospital, and VA Harbor Health Care System

Inci Irak Dersu, MD, MPH is a member of the following medical societies: American Academy of Ophthalmology, American Glaucoma Society

Disclosure: Nothing to disclose.

Additional Contributors

Neil T Choplin, MD Adjunct Clinical Professor, Department of Surgery, Section of Ophthalmology, Uniformed Services University of Health Sciences

Neil T Choplin, MD is a member of the following medical societies: American Academy of Ophthalmology, American Glaucoma Society, Association for Research in Vision and Ophthalmology, California Association of Ophthalmology, San Diego County Ophthalmological Society, Society of Military Ophthalmologists

Disclosure: Nothing to disclose.

Jerald A Bell, MD Staff Physician, Department of Ophthalmology, Billings Clinic

Jerald A Bell, MD is a member of the following medical societies: American Academy of Ophthalmology

Disclosure: Nothing to disclose.

Acknowledgements

The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous coauthors, Robert J Noecker, MD, and Emily Patterson, MD, to the development and writing of this article.

Sections Primary Open-Angle Glaucoma (POAG)
Overview
Presentation
- History
- Physical
- Causes
- Complications
- Show All
DDx
Workup
Treatment
Medication
Questions & Answers
Media Gallery
References

Primary Open-Angle Glaucoma (POAG) Questions & Answers

References

Tables

Contributor Information and Disclosures

What would you like to print?